HRS9531 Guide
Hengrui GLP-1/GIP Dual Agonist 2026
Complete guide to HRS9531 — Hengrui
What Is HRS9531 Guide?
HRS9531 is Hengrui Medicine\'s long-acting GLP-1/GIP co-agonist peptide. Like tirzepatide, it activates both the glucagon-like peptide-1 receptor and the glucose-dependent insulinotropic polypeptide receptor — but with a different amino acid backbone designed to optimize the receptor activation ratio. The FRUITION Phase 3 program enrolled patients with obesity in China, producing headline weight loss results that rival or exceed tirzepatide. HRS9531 represents the competitive next wave from Chinese pharmaceutical innovation challenging Western GLP-1 leaders in the multi-billion dollar obesity market.
Key Biohacking Mechanics
Appetite reduction via CNS signaling
Gastric emptying delay — extended fullness
Improved beta-cell function and insulin signaling
Same pathway as Ozempic/Wegovy
Amplifies insulin sensitivity (vs GLP-1 alone)
Improves fat cell metabolism
Potentiates GLP-1 effect when combined
Same pathway as Mounjaro (tirzepatide)
24.8% weight loss vs tirzepatide\'s 21%
52-week Phase 3 trial completed
Significant glucose improvement in T2D subgroup
Low discontinuation for adverse events
Subcutaneous injection once weekly
Same injection schedule as Mounjaro/Zepbound
Auto-injector pen format expected
Dose escalation protocol minimizes GI side effects
Expected Dosing Schedule
Starting dose — GI acclimatization phase
First escalation — meaningful efficacy begins
Standard maintenance dose in trials
Max dose — 24.8% weight loss achieved here
Note: Final approved dosing may vary. Follow your prescriber's guidance. Use Shotlee to log each weekly dose and monitor your progress.
Side Effects
Common Side Effects
Nausea (class effect — peak weeks 1-12). Vomiting. Diarrhea / constipation. Injection site reactions. Fatigue during dose escalation
Safety Profile
GI side effects similar to tirzepatide. All adverse events mild to moderate. Low discontinuation rates in FRUITION. No unexpected serious adverse events. Safety profile in line with GLP-1/GIP class
Development Timeline
2022-2023:
Phase 2 trials established dose-response and safety profile
2023-2024:
FRUITION Phase 3 trials completed — 24.8% weight loss
2025:
NMPA (China) regulatory submission under review
2026:
Potential China approval and global out-licensing discussions
Vital Protocol FAQs
Is HRS9531 better than Mounjaro?
Phase 3 data suggests HRS9531 may be more effective — 24.8% weight loss vs tirzepatide\'s 21% in SURMOUNT-1. However, these were separate trials with different populations, so direct comparison requir
Where can I get HRS9531?
HRS9531 is not yet approved or commercially available anywhere. It is currently awaiting NMPA approval in China, with global filings yet to be announced. It should not be sourced from research chemica
How do I track my weight loss progress while waiting for new GLP-1 drugs?
Use Shotlee to track your current GLP-1 medication, log weekly injection doses, monitor weight loss, and log side effects. Shotlee keeps you informed and accountable on your current journey.
Guide FAQs
Complete guide to HRS9531 — Hengrui
Yes. Shotlee supports tracking Hrs9531 doses, side effects, and health metrics. It is free to use.
References
Track Your Hrs9531 Protocol in Shotlee
Free dose logging, side effect tracking, and health metric monitoring for your complete protocol.
🚀 Use Shotlee for Free